|
|
|
08.12.25 - 14:36
|
Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump (24/7 Wall St.)
|
|
|
Abbott Laboratories (NYSE: ABT) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally different healthcare bets. Abbott delivered steady 6.9% revenue growth anchored by medical devices. Lilly posted explosive 54% revenue growth powered by its GLP-1 obesity and diabetes drugs. Medical Devices Carry Abbott. GLP-1s Carry Lilly. Abbott's medical device segment ... Lilly's GLP-1 Surge Dwarfs Abbott's Steady Device Growth With 54% Revenue Jump
The post Lilly's GLP-1 Surge Dwarfs Abbott's Steady Device Growth With 54% Revenue Jump appeared first on 24/7 Wall St.....
|
|
|
|
|
|
|
|
|
24.11.25 - 14:06
|
Q Holding Welcomes Gaurav Kapoor to its Board of Directors (Business Wire)
|
|
|
PEPPER PIKE, Ohio--(BUSINESS WIRE)--Q Holding (“QMD”) is pleased to announce the appointment of Gaurav Kapoor to its Board of Directors. Gaurav brings more than 25 years of experience across the medical device manufacturing and silicone engineering sectors. Most recently, Gaurav served as Chief Technical Officer of Spectrum Plastics (now part of DuPont), leading operational excellence initiatives and expanding the company's manufacturing and product development capabilities. In his prior role with the organization as Vice President of Manufacturing, he drove significant improvements in production efficiency, scalability, and product quality across 15 global sites. During his tenure at Spectrum, Gaurav was central to driving M&A strategy and execution. Prior to Spectrum, Gaurav held leadership roles at Hospira and Abbott Laboratories, where he focused on business planning, new product development, operational integration, and product quality.
Gaurav's deep experience in medical devices, technical exp...
|
|
|
20.11.25 - 18:54
|
Abbott to Buy Cancer-Screener Exact Sciences for $21 Billion (Bloomberg)
|
|
|
Abbott Laboratories agreed to acquire cancer-screening company Exact Sciences Corp., in a deal with a total equity value of about $21 billion.
In the biggest health-care deal in two years, Abbott will pay $105 per common share in cash, the companies said Thursday in a statement. The price represents a 51% premium to Exact Sciences' closing price on Nov. 18, the last full trading day before Bloomberg reported that Abbott was nearing a deal. Bloomberg's Matt Henriksson joins to discuss with Paul Sweeney and Scarlet Fu. (Source: Bloomberg)...
|
|
|
|
|
|
|
|
|
|
|
20.11.25 - 15:01
|
Abbott mit Paukenschlag: Mega-Übernahme fix (Der Aktionaer)
|
|
|
Der US-amerikanische Diagnostik-Riese verstärkt sich mit einer milliardenschweren Übernahme. Durch die Akquisition von Exact Sciences will sich die Gesellschaft im zukunftsträchtigen Bereich der Krebsdiagnostik besser positionieren. Doch der Preis, den Abbott Laboratories für die AKTIONÄR-Altempfehlung zahlt, ist hoch....
|
|
|
|
|
|
|
|
|
20.11.25 - 08:18
|
Abbott vor Mega-Deal? Gerüchte um Exact Sciences! (Der Aktionaer)
|
|
|
Steht der Diagnostik-Riese Abbott Laboratories vor einem milliardenschweren Zukauf? Wie die Nachrichtenagentur Bloomberg am Mittwoch berichtet hat, wollen sich die Amerikaner den Krebstest-Spezialisten Exact Sciences unter den Nagel reißen. Die Aktie des potenziellen Übernahmeziels sprang daraufhin um satte 24 Prozent in die Höhe....
|
|
|
|
|
|
|
21.10.25 - 04:45
|
JD HEALTH Forms In Vitro Diagnostics Alliance with Multiple IVD Brands (AAStocks)
|
|
|
JD HEALTH (06618.HK) announced yesterday (20th) that it recently partnered with well-known in vitro diagnostics (IVD) brands such as WONDFO (300482.SZ), Abbott Laboratories (ABT.US), COFOE MEDICAL (301087.SZ), INNOVITA (688253.SH) and KANGHUA BIOLOGICAL (300841.SZ) to initiate the 'JDH+N' JD HEALTH medical devices IVD br......
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
